Loading clinical trials...

Evaluating the Effects of Nitroglycerin on Heart Function and Urinary Output in Patients With Acute Heart Failure | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Evaluating the Effects of Nitroglycerin on Heart Function and Urinary Output in Patients With Acute Heart Failure

Impact of Nitroglycerin-induced Vasodilation on Stroke Volume and Diuretic Response in Acute Heart Failure: A Protocol for a Mechanistic Trial

NCT06682260•Copenhagen University Hospital, Hvidovre

View on ClinicalTrials.gov

Summary

This study aims to understand how nitroglycerin affects patients with acute heart failure, a condition where the heart struggles to pump blood effectively, leading to fluid buildup and breathing difficulties. Nitroglycerin relaxes blood vessels to ease the heart's workload and may help reduce fluid buildup. The investigators hypothesize that nitroglycerin can increase blood flow from the heart and promote urine production, which may reduce congestion in AHF patients. By studying heart function, blood volume, and fluid levels during treatment, the goal is to identify which patients may benefit most from nitroglycerin therapy.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age ≥ 18 years
•Clinical diagnosis of AHF requiring hospitalization
•Systolic blood pressure ≥85 mmHg
•Echocardiographic signs of cardiac dysfunction, by at least one of
•* Left ventricular ejection fraction ≤45%
•* Abnormal left ventricular filling with dilatation of the left atrium
•* Elevated filling pressures (systolic pulmonary artery pressure\>30, dilated vena cava inferior or E/é\>10)
•* Significant left-sided heart valve disease

Exclusion Criteria

•Ongoing ventricular taky- or brady-arrythmias or supraventricular arrhythmias with heart rate \> 180 or \< 40 bpm.
•Retinopathy or intraocular lens implantation (contraindication to Valsalva maneuver)
•Recent myocardial infarction or thromboembolic events.
•Intake of sildenafil or vardenafil withing 24 h and tadalafil within 48 h.
•Absolute contraindication for vasodilation using nitroglycerin as assessed by treating physician
•Intravenous administration of furosemide within 2 hours of baseline measurements

Locations (1)

Hvidovre Hospital

Copenhagen, Denmark

Key Dates

Start Date

February 1, 2025

Primary Completion Date

November 30, 2025

Completion Date

November 30, 2025

Last Updated

March 18, 2026

Enrollment

ACTUAL participants

Conditions

Acute Heart Failure (AHF)

Interventions

Nitroglycerin (NTG)

DRUG

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

RECRUITINGPHASE4

Digoxin After Acute Heart Failure

NCT07321509

Acute Heart Failure (AHF)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 18, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions